MTOR and nonpapillary renal cell carcinoma: Commonly used targeted drugs for ccRCC include tyrosine kinase inhibitors (TKIs), mechanistic target of rapamycin kinase (mTOR) inhibitors, immune checkpoint inhibitors, and hypoxia-inducible factor-2α inhibitors [10,11,12].